Having failed to meet its primary endpoint in consecutive Phase II studies, Galectin hopes to move GR-MD-02 forward in NASH in patients with cirrhosis who have not developed esophageal varices.
Galectin Therapeutics Inc. thinks subgroup analysis of its failed Phase IIb study in non-alcoholic steatohepatitis (NASH) highlights a way forward for its complex carbohydrate drug GR-MD-02, but investors don't seem to agree.
The Norcross, Ga., biotech reported Dec. 5 that GR-MD-02, targeting the galectin-3 protein which plays a role in fatty liver and fibrotic pathogenesis, failed to meet the primary endpoint of...
The UK major's asthma drug gets a key expanded approval.
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.
The French drugmaker is expanding its neurology activities with the $470m deal.
